



## Pharmaceutical Update

To cite this article: (1996) Pharmaceutical Update, Oncology Issues, 11:2, 10-10, DOI: [10.1080/10463356.1996.11904598](https://doi.org/10.1080/10463356.1996.11904598)

To link to this article: <https://doi.org/10.1080/10463356.1996.11904598>



Published online: 18 Oct 2017.



Submit your article to this journal [↗](#)



Article views: 1



View related articles [↗](#)

## Pharmaceutical Update

**R**esults of a randomized intergroup clinical trial comparing the chemotherapeutic agent fludarabine (Fludara, Berlex Laboratories) with chlorambucil were presented at the American Society of Hematology conference held in Seattle, Wash., in December. Fludarabine performs impressively in previously untreated patients with active chronic lymphocytic leukemia (CLL) when compared with chlorambucil, the drug most commonly used. Fludarabine is effective as second-line therapy in B-cell chronic lymphocytic leukemia and first-line treatment in low-grade non-Hodgkin's lymphoma.

Over a span of three-and-one-half years, more than 450 intermediate-risk and high-risk patients were accrued to compare the efficacy of fludarabine (F) 25 mg/m<sup>2</sup> by half-hour IV infusion daily from days one to five every four weeks versus chlorambucil (C) 40 mg/m<sup>2</sup> by mouth on day one every four weeks. Initially a third randomized arm combined the two drugs (F [20 mg/m<sup>2</sup>] and C [20 mg/m<sup>2</sup>]) but was closed when an interim analysis showed unacceptably high hematologic toxicity and a response rate no better than that achieved by fludarabine alone. The study, with a primary endpoint of complete remission, was comprised of two

phases: patients showing beneficial response received the assigned therapy for a maximum of twelve months, and nonresponding patients and those relapsing within six months were crossed over to the alternate therapy.

Of 233 evaluable patients, those in the fludarabine arm experienced a 36 percent complete remission rate, compared with 9 percent with chlorambucil. Fludarabine achieved a combined complete and partial response rate of 64 percent. It is too early to compare response duration and survival. Overall, both drugs were well tolerated with no significant difference between their toxicity profiles. ☐

### PROFESSIONAL OPPORTUNITIES AND CLASSIFIED ADVERTISING

#### COORDINATOR

Tumor Registry/Oncology Program

Plan and coordinate activities, workload, and staff of Tumor Registry. Analyze data, monitor trends and make recommendations based on findings. Collaborate with other departments regarding the delivery of oncology services and future potentials of the program. Candidates must be CTR or CTR eligible and have five years experience in Oncology program planning. Please fax resume to (402) 398-5539 or mail to: Alegent Health, Human Resources, Bergan Mercy Medical Center, 7500 Mercy Road, Omaha, NE 68124

 **Alegent Health**  
Equal Opportunity Employer

#### Advertising and Professional Opportunities 1996 Rates

##### Display Advertising

Frequency discounts and agency commissions do not apply.

2/3 page	725.50	1/3 page	498.50
1/2 page	630.00	1/4 page	405.75

##### Classified Section

*Oncology Issues* advertising rates are \$125 per column inch. Ads may be ordered in 1/2-inch increments: 1 1/2-inch ad=\$187.50; 2-inch ad=\$250; 2 1/2-inch ad=\$312.50. **Only prepaid orders will be accepted.** No agency commission is allowed on classified advertising.

#### DIRECTOR

Baptist Cancer Institute

Baptist Memorial Hospital, the largest private hospital in the country, has an excellent opportunity available for a Director of the newly formed Baptist Cancer Institute. Supported by a substantial grant from the Baptist Memorial Health Care Foundation, we are further developing our Cancer Clinical Research Programs, prevention, screen, and early detection services and community education and support.

Position requires experience in marketing, operations and strategic planning, program development, excellent communication skills, understanding of cancer research, and fiscal and technical management of the Baptist Cancer Institute.

Applicants must have 3-5 years in cancer program development. Master's degree in related field preferred.

BMH offers an excellent salary and benefits package. Interested candidates should send resume and salary history to:



**Baptist Memorial Hospital**

Joyce Owen, RN

Employment Services

20 South Dudley Street

Memphis, TN 38146

Tel (901) 227-4505 Fax(901) 227-6692

Equal Opportunity Employer